Northcape Wealth Management LLC Has $3.84 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Northcape Wealth Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,673 shares of the company’s stock after selling 1,217 shares during the quarter. Johnson & Johnson accounts for 1.3% of Northcape Wealth Management LLC’s holdings, making the stock its 23rd biggest position. Northcape Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,836,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Simplify Asset Management Inc. grew its position in Johnson & Johnson by 187.4% in the third quarter. Simplify Asset Management Inc. now owns 67,601 shares of the company’s stock valued at $10,955,000 after purchasing an additional 44,081 shares in the last quarter. Altrius Capital Management Inc grew its holdings in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Altrius Capital Management Inc now owns 28,634 shares of the company’s stock valued at $4,640,000 after acquiring an additional 412 shares in the last quarter. Archer Investment Corp increased its position in shares of Johnson & Johnson by 3.7% in the third quarter. Archer Investment Corp now owns 16,227 shares of the company’s stock valued at $2,630,000 after acquiring an additional 586 shares during the last quarter. Empowered Funds LLC raised its holdings in Johnson & Johnson by 8.8% during the third quarter. Empowered Funds LLC now owns 171,102 shares of the company’s stock worth $27,729,000 after acquiring an additional 13,910 shares in the last quarter. Finally, Empirical Finance LLC grew its stake in Johnson & Johnson by 2.0% in the third quarter. Empirical Finance LLC now owns 85,434 shares of the company’s stock valued at $13,845,000 after purchasing an additional 1,654 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Guggenheim increased their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Citigroup upped their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Trading Up 1.4 %

Shares of Johnson & Johnson stock opened at $153.99 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a market capitalization of $370.75 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.72 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s 50-day moving average price is $161.35 and its two-hundred day moving average price is $156.02.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 earnings per share. On average, analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.